Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study

References

• Stewart BW, Kleihues P. The world cancer report - the major findings. Cent Eur J Public Health 2003;11:177–9.
   PubMedGoogle Scholar
• Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–71.
   PubMed Web of Science ®Google Scholar
• Sewitch MJ, Fournier C, Ciampi A, Dyachenko A. Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol 2007;7:39.
   PubMedGoogle Scholar
• Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997;89:1406–22.
   PubMed Web of Science ®Google Scholar
• Agrawal J, Syngal S. Colon cancer screening strategies. Curr Opin Gastroenterol 2005;21:59–63.
   PubMed Web of Science ®Google Scholar
• Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935–53.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002;8:156–64.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS, Christensen IJ, Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer 2004;40:2159–64.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Brünner N, Jorgensen LN, Olsen J, Rahr HB, Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4,509 high risk individuals. Scand J Gastroenterol 2010; in press.
   Google Scholar
• Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700–10.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495–503.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen L, Jensen SB, Bardow A, Harslund J, Thaysen-Andersen M, Identifying sources and estimating glandular output of salivary TIMP-1. Scand J Clin Lab Invest 2008;68:548–54.
   PubMed Web of Science ®Google Scholar
• Hansen TV, Simonsen MK, Nielsen FC, Hundrup YA. Collection of blood, saliva, and buccal cell samples in a pilot study on the Danish nurse cohort: comparison of the response rate and quality of genomic DNA. Cancer Epidemiol Biomarkers Prev 2007;16:2072–6.
   PubMedGoogle Scholar
• Nielsen HJ, Brunner N, Frederiksen C, Lomholt AF, King D, Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 2008;43:242–8.
   PubMed Web of Science ®Google Scholar
• Hembry RM, Murphy G, Reynolds JJ. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci 1985;73:105–19.
   PubMed Web of Science ®Google Scholar
• Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991;30:8097–102.
   PubMed Web of Science ®Google Scholar
• Cooksley S, Hipkiss JB, Tickle SP, Holmes-Ievers E, Docherty AJ, Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990;10:285–91.
   PubMedGoogle Scholar
• Lindmark G, Bergstrom R, Pahlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 1995;71:1090–4.
   PubMedGoogle Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
   PubMed Web of Science ®Google Scholar
• Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;75:701–4.
   PubMed Web of Science ®Google Scholar
• Streckfus C, Bigler L, Tucci M, Thigpen JT. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest 2000;18:101–9.
   PubMed Web of Science ®Google Scholar
• Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000;6:2363–70.
   PubMed Web of Science ®Google Scholar
• Streckfus C, Bigler L, Dellinger T, Pfeifer M, Rose A, CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig 1999;3:138–43.
   PubMedGoogle Scholar
• Plante M, Wong GY, Nisselbaum JS, Almadrones L, Hoskins WJ, Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer. Obstet Gynecol 1993;81:989–92.
   PubMedGoogle Scholar
• Tylenda CA, Ship JA, Fox PC, Baum BJ. Evaluation of submandibular salivary flow rate in different age groups. J Dent Res 1988;67:1225–8.
   PubMed Web of Science ®Google Scholar
• Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 2000;79:1652–8.
   PubMed Web of Science ®Google Scholar
• Ghezzi EM, Wagner-Lange LA, Schork MA, Metter EJ, Baum BJ, Longitudinal influence of age, menopause, hormone replacement therapy, and other medications on parotid flow rates in healthy women. J Gerontol A Biol Sci Med Sci 2000;55:M34–42.
   PubMed Web of Science ®Google Scholar
• Ghezzi EM, Ship JA. Aging and secretory reserve capacity of major salivary glands. J Dent Res 2003;82:844–8.
   PubMed Web of Science ®Google Scholar
• Narhi TO, Meurman JH, Ainamo A, Nevalainen JM, Schmidt-Kaunisaho KG, Association between salivary flow rate and the use of systemic medication among 76-, 81-, and 86-year-old inhabitants in Helsinki, Finland. J Dent Res 1992;71:1875–80.
   PubMed Web of Science ®Google Scholar
• von Bultzingslowen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl):S57; e51-15.
   Google Scholar
• Somer E, Ben-Aryeh H, Laufer D. Salivary composition, gender and psychosocial stress. Int J Psychosom 1993;40:17–21.
   PubMedGoogle Scholar
• Holten-Andersen L, Thaysen-Andersen M, Jensen SB, Buchwald C, Højrup P, Salivary tissue inhibitor of metalloproteinases-1 localisation and glycosylation profile analysis. APMIS 2011;119:741–9.
   PubMedGoogle Scholar